orphenadrine has been researched along with Atherosclerotic Parkinsonism in 11 studies
Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.
orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A trial involving patients receiving fluphenazine decanoate was designed to compare the effects of orphenadrine hydrochloride (Disipal) and its major metabolite, tofenacin hydrochloride (Elamol) on the Parkinsonian side-effects and depression occurring during fluphenazine decanoate therapy." | 9.04 | A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy. ( Capstick, N; Pudney, H, 1976) |
| "A trial involving patients receiving fluphenazine decanoate was designed to compare the effects of orphenadrine hydrochloride (Disipal) and its major metabolite, tofenacin hydrochloride (Elamol) on the Parkinsonian side-effects and depression occurring during fluphenazine decanoate therapy." | 5.04 | A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy. ( Capstick, N; Pudney, H, 1976) |
| "Ritanserin is a new compound with a high, selective, and long-lasting binding affinity for 5-HT2 receptors." | 2.67 | 5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo. ( Bersani, G; Ciani, N; Grispini, A; Marini, S; Pasini, A; Valducci, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (90.91) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffman, BF | 1 |
| Mindham, RH | 2 |
| Korczyn, AD | 1 |
| Goldberg, GJ | 1 |
| Capstick, N | 1 |
| Pudney, H | 1 |
| Bersani, G | 1 |
| Grispini, A | 1 |
| Marini, S | 1 |
| Pasini, A | 1 |
| Valducci, M | 1 |
| Ciani, N | 1 |
| Altamura, AC | 1 |
| Mauri, MC | 1 |
| De Novellis, F | 1 |
| Percudani, M | 1 |
| Vampini, V | 1 |
| Vågen, R | 1 |
| Götestam, KG | 1 |
| Gaind, R | 1 |
| Anstee, BH | 1 |
| Rimmer, L | 1 |
| Morris, PA | 1 |
| MacKenzie, DH | 1 |
| Masheter, HC | 1 |
| Dogliani, P | 1 |
| Senini, G | 1 |
| Bertuzzi, F | 1 |
| Ekdawi, MY | 1 |
| Fowke, R | 1 |
7 trials available for orphenadrine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Assessment of drugs in schizophrenia. Asessment of drug-induced extrapyramidal reactions and of drugs given for their control.
Topics: Amantadine; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Clinical Trials as T | 1976 |
Extrapyramidal effects of neuroleptics.
Topics: Adult; Age Factors; Antipsychotic Agents; Clinical Trials as Topic; Dyskinesia, Drug-Induced; Extrap | 1976 |
A comparative trial of orphenadrine and tofenacin in the control of depression and extrapyramidal side-effects associated with fluphenazine decanoate therapy.
Topics: Clinical Trials as Topic; Depression; Fluphenazine; Humans; Orphenadrine; Parkinson Disease, Seconda | 1976 |
5-HT2 antagonist ritanserin in neuroleptic-induced parkinsonism: a double-blind comparison with orphenadrine and placebo.
Topics: Adolescent; Adult; Double-Blind Method; Female; Humans; Male; Middle Aged; Orphenadrine; Parkinson D | 1990 |
An experimental evaluation of the euphoric properties of antiparkinson drugs on psychotic patients.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Double-Blind Method; Euphoria; Female; Humans; Male; | 1986 |
Comparison of amantadine, orphenadrine, and placebo in the control of phenothiazine-induced Parkinsonism.
Topics: Affect; Amantadine; Basal Ganglia Diseases; Clinical Trials as Topic; Evaluation Studies as Topic; F | 1972 |
A comparative double blind trial of pimozide and fluphenazine in chronic schizophrenia.
Topics: Benzimidazoles; Blood Cell Count; Clinical Trials as Topic; Fluphenazine; Humans; Male; Middle Aged; | 1970 |
4 other studies available for orphenadrine and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
The diagnosis and treatment of neuroleptic-induced Parkinsonism.
Topics: Antipsychotic Agents; Depression; Diagnosis, Differential; Diphenhydramine; Humans; Neurologic Exami | 1981 |
Residual neuroleptic-induced parkinsonian symptoms in schizophrenia. A naturalistic study with orphenadrine.
Topics: Adult; Aged; Female; Haloperidol; Humans; Male; Middle Aged; Orphenadrine; Parkinson Disease, Second | 1989 |
Clinical observations on the therapeutic activity of flupentixol in the treatment of chronic schizophrenia.
Topics: Adult; Aged; Blood; Body Weight; Chlorpromazine; Chronic Disease; Delusions; Depression, Chemical; F | 1970 |
A controlled trial of anti-Parkinson drugs in drug-induced Parkinsonism.
Topics: Adolescent; Adult; Chlorpromazine; Haloperidol; Humans; Middle Aged; Orphenadrine; Parasympatholytic | 1966 |